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Background: The R518X/KCNQ1 mutation is a common cause of autosomal recessive (Jervell and Lange Nielsen
Syndrome- JLNS) and autosomal dominant long QT syndrome (LQTS) worldwide. In Sweden p.R518X accounts for
the majority of JLNS cases and is the second most common cause of LQTS. Here we investigate the clinical
phenotype and origin of Swedish carriers of the p.R518X mutation.
Methods: The study included 19 Swedish p.R518X index families, ascertained by molecular genetics methods (101
mutation-carriers, whereof 15 JLNS cases and 86 LQTS cases). In all families analyses included assessment of clinical
data (symptoms, medications and manually measured electrocardiograms), genealogy (census records), haplotype
(microsatellite markers) as well as assessment of mutation age and associated prevalence (ESTIAGE and DMLE
computer software).
Results: Clinical phenotype ranged from expectedly severe in JLNS to surprisingly benign in LQTS (QTc 576 ± 61 ms
vs. 462 ± 34 ms, cumulative incidence of (aborted) cardiac arrest 47% vs. 1%, annual non-medicated incidence rate
(aborted) cardiac arrest 4% vs. 0.04%).
A common northern origin was found for 1701/1929 ancestors born 1650-1950. Historical geographical clustering in
the coastal area of the Pite River valley was shown. A shared haplotype spanning the KCNQ1 gene was seen in 17/
19 families. Mutation age was estimated to 28 generations (95% CI 19;41). A high prevalence of Swedish p.R518X
heterozygotes was suggested (~1:2000-4000).
Conclusions: R518X/KCNQ1 occurs as a common founder mutation in Sweden and is associated with an
unexpectedly benign phenotype in heterozygous carriers.
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Loss-of-function mutations in the KCNQ1 gene cause
both the autosomal recessive Jervell and Lange-Nielsen
syndrome (JLNS) and the autosomal dominant type
1 long QT syndrome (LQTS), also known as the
Romano-Ward syndrome [1]. The KCNQ1 gene en-
codes the α-subunit of a voltage-gated potassium ion
channel (Kv7.1) regulating both inner ear endolymph
flow and cardiac action potential duration via the de-
layed rectifier potassium current (IKs). Kv7.1 function
loss corresponds to congenital hearing loss in JLNS, as
well as variable QT prolongation and propensity for
arrhythmia, presenting as syncope or (aborted) cardiac
arrest, in both syndromes.
Several hundred different mutations with variable ef-
fect on Kv7.1 function have been reported, and while
mutation-specific risk-stratification could be of consider-
able clinical importance in LQTS, few mutations are
common enough to allow such characterization [2].
In Sweden, two KCNQ1 mutations dominate the
mutation spectrum regarding LQTS and JLNS [3,4]. The
p.R518X and p.Y111C mutations account for over 25%
of Swedish LQTS index cases with identified mutations
[3], and p.R518X alone has been identified as the major
cause of JLNS in Sweden [4]. Regarding p.Y111C, strong
founder effects during the population development of a
northern river valley region have previously been shown
to result in the enrichment of this specific founder mu-
tation in the population [5,6].
Here we investigate the clinical phenotype and founder
nature of the R518X/KCNQ1 mutation, a worldwide
known hotspot mutation and a common cause of JLNS
and LQTS [2,7-9], in the Swedish population.
Methods
Case ascertainment
Index families (n = 19) carrying the p.R518X mutation
[c.1522C > T] were identified between 2001 and 2011
through the regional LQTS Family Clinic, Centre for
Cardiovascular Genetics and/or national clinical referrals
to the department of Clinical Genetics, both at Umeå
University Hospital, Umeå, Sweden (Figure 1). Case as-
certainment was performed using genomic DNA ex-
tracted by a standard salting-out procedure. Genotypes
in p.R518X probands (10 LQTS index cases and 9 JLNS
index cases) were ascertained by denaturing high-
performance liquid chromatography (Wave 3500 HT,
Transgenomic, Inc, Omaha, Neb) and/or sequencing all
coding exons of the KCNQ1 gene (CEQ 8000, Beckman
Coulter, Fullerton, CA, USA), according to current clin-
ical practices for molecular genetics diagnostics. The
presence of possible additional mutations in the other
major LQTS genes (KCNH2, SCN5A and KCNE1) was
subsequently investigated and negated in 6/10 LQTSprobands. Genotype was ascertained in all 9 probands
of JLNS genotype, whereof all carried double KCNQ1
mutations (including three of homozygous p.R518X
genotype (p.R518X/p.R518X) and 6 of compound hetero-
zygous genotype (p.R518X and p.M159 splice error [c.477 +
1G>A], p.R190W [c.568C >T], p.Q530X [c.1588C >T],
p.S349W [c.1046C >G], or p.S227del [c.828_830del]). In
family members (n = 164) mutation carrier-ship was ascer-
tained by sequencing or targeted mutation analysis of the
identified mutation (MGB-probes by ABI 7000, Applied
Biosystems, Foster City, CA, USA). Index families com-
prised the first ascertained index case/proband in a family
without known relations to any other LQTS family, plus all
tested family members identified through the process of
cascade-screening of first-grade relatives [5]. All p.R518X
index families identified during the time period 2001-2011
were invited to participate in the study. Participants, or their
legal guardian, signed an informed consent and the study
was approved by the Regional Ethical Committee in Umeå,
Umeå University, Sweden.
Clinical phenotype
All living p.R518X mutation-carriers (n = 97) answered a
questionnaire regarding personal LQTS history (occur-
rence of symptoms and beta-blocker therapy duration
and compliance). Symptomatic cases were interviewed
by one of the authors regarding symptoms (debut, type,
frequency and triggers). Anamnestic data regarding four
deceased JLNS siblings was obtained during an interview
with their living sibling. The data included information
regarding deafness, cardiac symptoms (debut, type and
frequency) and age at, and cause of, death.
Symptomatic LQTS was defined as syncope/transient
but complete loss of consciousness. Life-threatening car-
diac events were defined as aborted cardiac arrest re-
quiring resuscitation or as sudden cardiac death.
QT interval duration was measured manually, prefera-
bly in lead II as a mean of three consecutive QT inter-
vals, and corrected for heart rate by Bazett’s formula
(QT/√R-R), using the mean of the R-R intervals (lead
III) preceding the measured beats, in standard 12- lead
electrocardiograms obtained from medical records, when
available recorded in absence of beta-blocker therapy.
Beta-blocker therapy was not discontinued in any
mutation-carrier in order to obtain a recording in ab-
sence of therapy.
Statistical analyses regarding clinical phenotype
Clinical parameters were explored within p.R518X geno-
type groups using Chi-square test (Fisher’s Exact test, for
correlations between nominal variables), and Nonpara-
metric test (Mann Whitney U test, for analysis of variance
between continuous (scalar) and nominal variables). To
assess the interfamilial variation of phenotype, the annual
Figure 1 Geographic location of Umeå situated in northern Sweden, Scandinavia (upper left corner, bordering on Norway to the west
and the Gulf of Bothnia and Finland to the east). Rivers in the northern region are depicted as lines.
Winbo et al. BMC Cardiovascular Disorders 2014, 14:22 Page 3 of 10
http://www.biomedcentral.com/1471-2261/14/22incidence rate of life threatening cardiac events in absence
of beta-blocker therapy in p.R518X heterozygotes was
compared to that of a large mixed LQT1 population [10],
by Fisher’s Exact test. For clinical parameters a two-tailed
value for p < 0.05 was considered statistically significant.
Investigating the origin of the p.R518X mutation
Genealogical investigations were performed using par-
ish records and genealogical databases at the Umeå
University research archive and the Swedish archive in-
formation homepage (www.svar.ra.se). Both parental
lineages were investigated at least up until 1750, and
when possible traced back to the 16th century. Birth-
places of ancestors born between 1650 and 1950 were
noted on regional maps to assess geographical cluster-
ing, over time.
A haplotype analysis, using 14 microsatellite markers
flanking the KCNQ1 gene (Figure 2), spanning over adistance of approximately 8 × 106 base pairs, was per-
formed in all 19 p.R518X index families and 168 control
chromosomes from healthy military recruits of northern
Swedish origin [5]. Haplotype analysis was preferentially
performed in mutation-carriers pertaining to two separ-
ate generations in each index family (two carriers in
LQTS/compound heterozygous JLNS index families and
three carriers in homozygous JLNS index families) in
order to aid in resolving the mutation-associated haplo-
type. The allele, for each marker, shared by both carriers
was interpreted as the mutation-associated allele. In
cases where two different alleles were present in both
generations, the pattern from all included index families
was used to reconstruct the most likely founder/ances-
tral haplotype. The control data was used to assess
whether the observed pattern could be due to random
chance. Fragment analysis was performed according to
the manufacturers’ instructions (forward and reverse
Figure 2 Overview of the chosen microsatellite markers used for haplotype analysis, including 14 microsatellite markers
(nomenclature D11S- followed by the number under the arrows) flanking the KCNQ1 gene, spanning over a distance of ~8 cM (8 × 106
base pairs). The p.R518X mutation location in KCNQ1 is indicated by the vertical black line. Physical distances between the p.R518X mutation
and each marker are given above. The grey arrowhead indicates the location of the D11S-1318 marker included in the p.Y111C haplotype analysis
that was excluded in the current analysis due to a generally low quality of peaks and a high frequency of background noise.
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PCR product analyzed using an automated capillary elec-
trophoresis based DNA Sequencer (Wave® 3500 HT,
Transgenomic Inc, Omaha, Nebraska). Solutions and
material for PCR mix were manufactured by GE Health-
care (United Kingdom) and Applied Biosystems (Foster
City, California). The microsatellite data was analyzed
using GeneMapper software version 3.7 (Applied Biosys-
tems, Foster City, CA, USA).
Mutation age and prevalence estimations
The age of a mutation can be inferred by assessing the
frequency of an allele, or the decay secondary to muta-
tions and/or recombination of an ancestral haplotype
over the generations in a sample of probands sharing
mutations identical by descent [11,12]. In p.R518X index
families sharing a common haplotype, the distance (in
generations) from the included probands to the most re-
cent common ancestor (an approximation of mutation
age) as well as the associated prevalence of founder de-
scendants (as a function of mutation age) were estimated,
including 95% confidence intervals (95% CI), using the
ESTIAGE software [13] and DMLE freeware (available at
www. dmle.org).
The mutation age estimate, as calculated by the ESTI-
AGE software, included haplotype data, allele frequencies
from healthy controls, and recombination frequencies for
the microsatellite markers. The haplotype data included
the extent of shared alleles among probands, counting
from the gene and outwards, excluding shared alleles dis-
tant of any marker with discordant alleles. The allele fre-
quencies from healthy controls included the proportion of
the founder allele, per marker, in a sample of 168 control
chromosomes of northern Swedish origin. The recombin-
ation frequencies were derived from the physical distances
between the mutation and the microsatellite markers, cal-
culated using the standard correspondence 1 cM= 106
base pairs. Separate estimates were performed in order to
assess the potential impact of the assumed mutation rate
(10-6 to 10-4) as well as the mutation model used (stepwise
or equal).
The approximation of p.R518X prevalence as a func-
tion of mutation age, as calculated by the DMLEsoftware, included haplotype data from families sharing
a common haplotype, regional population growth rates
and an estimate of the proportion of population sam-
pled. The haplotype data included the full haplotype of
both p.R518X families and controls for all analysed
markers. The regional population growth rate was ana-
lysed as a discrete variable = e^(ln [end population/start
population]/number of generations) -1), calculated using
population demographics data available from Statistics
Sweden (www.scb.se). The proportion of population sam-
pled was viewed as the unknown variable and iterations
were performed over the interval 0.0001-0.5, within a
range of possible values for mutation age (defined as
the overlap between the 95% confidence intervals of
the ESTIAGE and DMLE mutation age estimates). The
upper limit of acceptable values for the variable propor-
tion of population sampled was corrected for the num-
ber of ascertained mutation-carriers in the population.
Results
Study population and p.R518X-associated clinical
phenotype
Cascade-screening in 19 Swedish p.R518X Swedish index
families identified 97 p.R518X mutation-carriers (includ-
ing probands) and 73 non-carriers. Among the ascertained
mutation-carriers, 11 were JLNS cases (4 homozygous,
7 compound heterozygous) and 86 were heterozygous
LQTS cases. Additionally, 4 deceased JLNS cases with
available anamnestic and clinical data, siblings to a JLNS
case with ascertained homozygous p.R518X genotype,
were included in the study. Characteristics of the p.R518X
study population, stratified by genotype (JLNS/LQTS), are
summarized in Table 1.
JLNS cases (n = 15, QTc 576 ± 61 ms, range 461-
697 ms) presented with congenital hearing loss and a
severe cardiac phenotype (early symptoms debut and
a high frequency of life-threatening cardiac events, in-
cluding three sudden deaths, Table 1). A more severe
phenotype for homozygous as compared to compound
heterozygous JLNS cases was suggested in this limited
material, but did not reach statistical significance (syn-
cope 100% vs. 57%, p = 0.077; QTc 622 ± 64 ms vs. 550 ±
45 ms, p = 0.089).




Females 8 (53) 54 (63)
Age at last follow-up, years 29 ± 23, 28 34 ± 21, 37
Non-medicated follow-up, years 16 ± 20, 9 31 ± 21, 33
Experience of first cardiac event 12 (80) 15 (17)
Age at onset, years 2 ± 1, 3 18 ± 15, 12
Experience of ACA/SCD 7 (47) 1 (1)
Number of events 9 1
Non-medicated life-years, n 241 2466
Annual incidence rate before therapy,%c 4 0.04
Triggers of symptoms,%
Exercise/Swimming/Emotions/Other 46/ 12/ 2/ 20 44/ 2/ 22/ 32
ECG (% recorded off therapy) 11d (27) 81 (73)
QTc, mse 576 ± 61, 560 462 ± 34, 459
<440 ms 0 (0) 20 (25)
≥500 ms 10 (91) 13 (17)
Heart rate, bpm 77 ± 23, 75 73 ± 20, 69
Beta-blocker therapy 11f (73) 37 (43)
Age at therapy start, years 8 ± 15, 2g 25 ± 19, 17
Abbreviations: JLNS- Jervell and Lange-Nielsen syndrome, LQTS- long QT
syndrome, ACA- aborted cardiac arrest requiring resuscitation (not including
device therapy), SCD- sudden cardiac death.
a Values are expressed as number of patients (percentage of total), or as
mean ± standard deviation, followed by median, if not otherwise specified.
b Clinical data on JLNS cases have been previously described together with all
identified Swedish JLNS cases, by our group [4]. JLNS cases in family JLN5
have been described previously by others, [14] our study is based on contact
with the proband in 2010.
c Calculated as number of life-threatening events/sum of non-medicated life
years (×100).
d Electrocardiograms were not available from the four deceased JLNS cases in
family JLN5.
e Intra-observer measurement error 0.4 ± 5.7 ms between repeated measure-
ments, coefficient of variation 0.1%.
f All now living JLNS cases were on beta-blocker therapy.
g Among JLNS cases born from 1980 and onwards (n=8), 3 received
beta-blockers during the first year of life and the remaining 5 received
beta-blockers during the first 3 years of life.
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545 ms) presented with a relatively benign overall
phenotype (Table 1). Fifteen LQTS cases (17%) had ex-
perience of syncope during a mean follow up of 31 ±
21 years (median 33) before therapy. One case died sud-
denly and there were no aborted cardiac arrests reported
(cumulative incidence of life threatening events 1.2%, an-
nual incidence rate before therapy 0.04%). This corre-
sponds to a low incidence of life-threatening cardiac
events, as compared to a large LQT1 population [10]
(0.04% vs. 0.3%, p = 0.007). The sudden cardiac death oc-
curred in a previously asymptomatic adult female in
family JLN2 (age 56 years) with a QTc of 506 ms withoutprophylactic beta-blocker therapy, in relation to physical
exercise and hypokalaemia (probably diet-induced).
QTc in LQTS cases showed variability between males
and females (443 ± 29 ms vs. 473 ± 33, p < 0.001) as well
as within genders (range 397-521 ms in males; 402-
545 ms in females). Based on age- and gender adjusted
QTc levels [15], 46% of LQTS cases had a prolonged
QTc while 54% had a borderline (28%) or normal QTc
(27%). Among LQTS males, the corresponding propor-
tions were 34%, 28% and 38%. Among symptomatic
LQTS cases (n = 15), QTc ranged between 402-545 ms
and 33% (five cases, whereof two males) had a QTc
below 440 ms. In symptomatic LQTS cases (n = 15,
whereof five males) phenotypic variability was evident
regarding age at onset (1.5-56 years), cardiac event
frequency (1- >10) and QTc (402-545 ms). Five symp-
tomatic cases (33%) had a QTc below 440 ms (whereof
two males).
No significant indicators of risk for cardiac events were
found when assessing the distribution of the following
variables across the categories symptomatic and asymp-
tomatic heterozygous p.R518X carriers; QTc ≥500 ms
(p = 0.061), gender (p = 0.56), heart rate (p = 0.112) and
scalar QTc prolongation (p = 0.622).
Symptomatic LQTS cases (n = 15) were equally found
in families with JLNS and LQTS probands (7 vs. 8), i.e.
several LQTS probands were investigated for other rea-
sons than previous experience of syncope, such as palpi-
tations, dizziness or chance findings of a prolonged QTc
on the electrocardiogram.
With regards to therapeutic interventions, these were
performed earlier and more frequently in JLNS cases as
compared to LQTS cases. Four JLNS cases (all born be-
fore 1950) died prior to beta-blocker therapy, at the age
of 20, 27, 37 and 59 years, respectively. Among the 11
JLNS cases treated with beta-blockers, two cases were
treated with left cardiac sympathetic denervation (age 2,
24 years) and four cases, including the previous two, re-
ceived implantable cardioverter defibrillators (age 5, 10,
19 and 32 years), due to recurrent syncope in spite of
therapy. All cases with implantable cardioverter defibril-
lators (n = 4) have experienced appropriate shocks, ac-
cording to their medical records. In LQTS cases beta-
blocker therapy (43% of cases, Table 1) was associated
with only one case experiencing a first syncope while on
therapy, and no recurrences in 11 previously symptom-
atic cases with adequate dosage, while compliant.A common origin established using genealogy and
haplotype analysis
Genealogical investigation in the 19 p.R518X index families
revealed several genealogical interconnections, whereof a
couple born 1702/1703 in the Pite River Valley region
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proximately 300 years (Figure 3).
Analysis of the birth places of all identified p.R518X
ancestors born between 1650 and 1950 (n = 1929) re-
vealed a northern origin in 88% (n = 1701) and geo-
graphical clustering, over time, in the upper northern
region with focus around the coastal area where the Pite
River accesses the Gulf of Bothnia (Figure 4).
Analysis of microsatellite markers in the 19 p.R518X
index families (with haplotype data available from two
separate generations in 15/19 families, in total 36
mutation-carriers) and 168 control chromosomes re-
vealed a shared haplotype of uncommon alleles (control
frequency 0.006-0.46, median 0.18) over 4-14 marker
loci (median seven) for 17/19 families (Figure 5). Two
probands (JLN9 and LQT10) did not share the founder
haplotype but between themselves shared six markers
spanning over the KCNQ1 gene. The two families that
did not share the founder haplotype (JLN9 and LQT10)
included only two ascertained mutation-carriers (the pro-
bands). Additionally, one parent of a homozygous p.R518X
proband (JLN3) had a third, separate, haplotype. Conse-
quently, in total 98/101 included cases pertained to the
founder population.Figure 3 Pedigree illustrating the results from the genealogical
investigation performed in the 19 Swedish p.R518X index
families. The pedigree includes ascertained p.R518X mutation-
carriers from five index families (n = 33, filled symbols, including two
JLNS cases) connected by an ancestor couple born ~10 generations
previously in the early 18th century (1702/1703). Index cases are
indicated by arrows. Mutation-carriers in the most recent generation
are depicted as filled diamonds, and JLNS genotype not specified, in
order to preserve the anonymity of cases. The male (square) marked
with an asterisk in generation 7 was married to a descendant of the
female (circle), also marked with an asterisk, in generation 3. This
alternative route of possible inheritance of the p.R518X mutation
was omitted for legibility.
Figure 4 Map of northern Sweden illustrating the clustering of
birth places (dots) of p.R518X ancestors born between 1650
and 1950. Bold dots represent parishes where ancestors from ≥3
index families co-resided during the same time-period (1650-1749,
1750-1849 and/or 1850-1949). For each time-period the area
delimited by the bold dots was shaded, resulting in a darker colour
in the region with highest concentration of p.R518X ancestors over
time. The number of p.R518X ancestors born in each parish (whereof
93% born between 1650 and 1850) is given, followed by the
maximum number of co-residing families during a single
time-period (in parenthesis).Mutation age and prevalence estimate
The age of the identified founder haplotype was esti-
mated to 28 generations (95% CI 19;41) assuming a mu-
tation rate of 10-6, by ESTIAGE computer software.
Estimates were not affected by type of mutation model
used and only slightly by mutation rate (Table 2). The
estimate corresponds to a mutation age of 700 years
(95% CI 475-1025), when assuming 25 years per average
generation. By DMLE computer software, the sampled
probands with a shared haplotype (n = 17) were esti-
mated to account for 2-4% of the entire p.R518X popu-
lation (proportion of population sampled 0.02-0.04), for
growth rates between 25-27% and mutation ages be-
tween 26-29 generations, with a best fit approximating
0.03. The estimate predicts between 425-850 p.R518X
Figure 5 The ancestral haplotype (x-axis) of 19 p.R518X index families (y-axis) was reconstructed, identifying 17 founder families
(families JLN1-8, LQT1-9). An overview of the 14 analysed markers and their locations is given above. The C-terminal location of the p.R518X
mutation in the KCNQ1 gene is indicated by the vertical black line. Shared alleles (4-14, median 7) are shaded in grey. The proportion of the
founder alleles found in 168 control chromosomes is given for each marker (bottom). Families JLN9 and LQT10 shared only one of the
downstream mutation-associated markers adjacent to the KCNQ1 gene, but between themselves shared six markers spanning over the KCNQ1
gene, indicating that these two families are related to each other.
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p.R518X mutation-carrier prevalence of ~1: 2000-4000
in Sweden (population ~9.5 × 106, Table 3).
Discussion
In this study, we identified 101 Swedish cases (15 JLNS,
86 LQTS) in 19 index families segregating the R518X/
KCNQ1 mutation, and revealed that the common occur-
rence of this specific mutation in the Swedish population
is related to founder effects.
A benign phenotype and remaining variability
While the p.R518X-associated phenotype in JLNS cases
was expectedly severe (resulting from a near-complete
loss of Kv7.1 function), an unexpectedly benign pheno-
type was seen in LQTS cases. When in the heterozygous
form, the p.R518X nonsense mutation has been shown
to cause Kv7.1 haploinsufficiency, in vitro [16]. As forTable 2 ESTIAGE mutation age estimates results, in
generations including 95% confidence intervals
Mutation rate Mutation model
Stepwise Equal
10-4 27 (18;41) 27 (18;41)
10-6 28 (19;41) 28 (19;41)p.R518X, it is common for heterozygous nonsense muta-
tions to present with relatively mild phenotypes, as the
resultant protein products cannot co-assemble with wild
type subunits and therefore seldom cause dominant-
negative effects [17]. However, as compared to 169 het-
erozygous carriers of KCNQ1 mutations causing hap-
loinsufficiency, described by Moss et al [18], the clinical
phenotype of the p.R518X founder heterozygotes still
appear to be less severe (aborted cardiac arrest 3% vs. 0,
sudden death 2.4% vs. 1.2%). The annual incidence rate
of life-threatening cardiac events before therapy in the
p.R518X founder heterozygotes is comparable to that of
another unexpectedly benign Swedish founder popula-
tion (0.04% vs. 0.05%), segregating the dominant nega-
tive p.Y111C mutation [5,6]. The benign phenotypes of
the LQTS river valley populations in Sweden remain
unexplained.
The popular notion that founder mutations would by
their nature be benign is negated by the severe pheno-
type of the A341V/KCNQ1 mutation that segregates
within a South African founder population, and is asso-
ciated with a staggering 30% cumulative incidence
of life-threatening cardiac events [19]. As in the case
with the Boer progeny [20], a substantial intra-familial
phenotypic variability regarding clinical phenotype
remained in the p.R518X founder population, and the
















17 26-29 25-27 0.02-0.04 0.03 425-850 ~1:2-4000
Estimates calculated using the DMLE computer software (http://www.dmle.org).
a In generations.
b Calculated as: the Swedish population size/(estimated probands × [identified mutation-carriers in founder families/probands]), i.e.:
(lower bound) 9.5 × 106/ (425 × [99/17]) = 1:3838.
(upper bound) 9.5 × 106/ (850 × [99/17]) = 1:1919.
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correlate with gender, heart rate nor, surprisingly, QTc.
The commonly occurring p.R518X mutation
In the international context p.R518X is commonly de-
scribed as a hotspot mutation, reported as a common cause
of JLNS [8,9,16], as well as one of the five most common
mutations in Northern American LQTS probands [2]. In
Sweden, the p.R518X mutation has previously been re-
vealed as the major cause of JLNS, contributing to the
JLNS genotype in 9/12 identified JLNS index families
with ascertained genotype (12/24 alleles) [4]. The im-
portance of the p.R518X allele also with regards to the
Swedish LQTS mutation spectrum was indicated by the
finding that p.R518X was the second most commonFigure 6 The geographic distribution of the two northern river valley
mutations Y111C/KCNQ1 (left) and R518X/KCNQ1 (right).mutation identified in 200 Swedish index cases referred
for LQTS diagnostics at the laboratory of Clinical
Genetics, Umeå University Hospital, between 2006
and 2009 [3]. The cohort included LQTS index cases
(excluding JLNS probands) originating from all six
Swedish health care regions, whereof 78% from without
the northern region. Together with p.Y111C (the most
commonly identified mutation) these two mutations
accounted for over 25% of index cases with ascertained
genotype (n = 102) [3].
While the majority of the Swedish p.R518X JLNS and
LQTS probands have now been identified as pertaining
to a founder population, the additional finding of two
p.R518X probands, as well as one parent to a homozy-
gous p.R518X case, lacking the founder haplotyperegions identified as the origins of the Swedish LQTS founder
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mutation in the Swedish setting. In parallel, in our
neighbouring country Norway, with which we share cul-
tural and linguistic similarities, geographical proximity,
history (political union 1814-1905), as well as marked
similarities regarding the JLNS mutation spectra [4], the
p.R518X mutation also occurs both as a hotspot and a
founder mutation [21]. These findings are in no way
controversial, as the frequent occurrence of a particular
mutation (which in this case also is associated with a
relatively benign phenotype) would intuitively make it
more likely to happen to partake in a founder effect
given the right population-developmental circumstances.
As we have shown for the Y111C/KCNQ1 founder muta-
tion [5], congruent genealogical and haplotype data
including mutation dating placed the founding of the
p.R518X population in a northern river valley region
around the 14th century, coinciding with the early phase
of a royal initiative to populate the upper northern re-
gions of Sweden [22]. The geographical location of the
separate river valley regions of the Swedish founder mu-
tations is presented in Figure 6. As for p.Y111C, the
combination of a low number of original founders, a
slow initial population growth, a geographical isolation
of the river valleys, and a preference to marry within the
river valley region, probably promoted the enrichment
of founder alleles in the Swedish population [5,23]. As
a curiosity, in spite of the common occurrence of the
p.R518X and p.Y111C mutations in the northern region
and the high frequency of JLNS cases, no case with
p.R518X/p.Y111C genotype has been identified, the rea-
son for which remains unknown [4].
Limitations
The major LQTS genes were not analysed in 4/10 LQTS
probands, negating the possibility of identifying additional
mutations contributing to phenotype in these cases.
The p.R518X prevalence estimate of ~1:2000-4000
presented in this study is based on extrapolations from
genetic, genealogical and epidemiological data, and as
such should be interpreted with caution. Being derived
from data on the founder population the estimates do
not include calculations regarding p.R518X cases sec-
ondary to hotspot effects (risk of underestimation). Also,
regional differences in prevalence with regards to distri-
bution of mutation-carriers are to be expected (i.e.
higher prevalence in the northern region and the major
urban regions in the south that have received the major-
ity of the 20-21th century migration). The p.R518X
prevalence estimate of ~1:2000-4000 is supported by the
high frequency of both founder (n = 14) and non-
founder JLNS cases (n = 1) with p.R518X mutations
identified in the population, the high contribution of the
specific p.R518X allele to the Swedish JLNS mutationspectrum [4], as well as congruent prevalence estimates
in the Norwegian population [9].
Conclusions
The common occurrence of the p.R518X mutation
among Swedish probands with recessive and dominant
type LQTS is mainly secondary to a founder effect. Our
findings suggest a high prevalence of the p.R518X
founder mutation in the Swedish population. In the clin-
ical setting, due to the low penetrance of clinically iden-
tifiable markers in p.R518X heterozygotes, molecular
genetics diagnosis of probands and cascade-screening of
first-degree relatives remains imperative in order to
identify individuals at risk of developing preventable
arrhythmia.
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